Fresenius To Upgrade I.V. Fluid Units To European Standard
Fresenius Kabi, the European leader in infusion and nutrition therapy, which has strong market presence in emerging markets including India, would upgrade its manufacturing facilities all across the world to European quality standards. As part of this global facility standardization, the company's Indian facility located at Ranjangaon near Pune is also getting upgraded to the EU quality norms.
Medtronic Offers Insulin Pumps In Indian Market
Medtronic offers Model 508 series insulin pumps to help insulin dependent patients improve their blood sugar control. In fact, maintaining near normal blood sugar levels using predictable, rapid acting insulin, delivered precisely and on command by an insulin pump can help
Auto Disable Syringes : Hindustan Medical Devices (HMD) Tie Ups With Pharma Multinationals
Hindustan Medical Devices (HMD), the lone domestic manufacturer of auto disable (AD) syringes, is currently on a deal signing spree with many of the pharma multinationals and some of the domestic pharma companies for supply of these syringes. The pharma companies procure these syringes for free supply along with their injections as part of their campaign to promote safe injection practices.
US Pharmacopeia Sets Up India Site
The United States Pharmacopeia (USP) announced setting up its India site, consisting of its business operations and laboratories which will offer USP's broad range of Pharmacopeia services to Pharma companies in India and neighbouring countries.
Medical Devices Bill : Before Parliament Soon
The draft Bill seeking to introduce a regulatory system for medical devices used in clinical applications will be introduced in the parliament soon. The Bill with certain key provisions, was discussed by the Drug Technical Advisory Board and is forwarded by the DCC subcommittee.
Pharma Packaging : Bilcare's Expansion plan for
Fitch Ratings India has assigned an 'A-(ind)' rating to Bilcare's Rs. 400-m
long-term debt programme. The rating outlook is stable. The rating reflects the
company's established position in the blister-packaging segment in the country,
research and development (R&D) capabilities and a track record of steady
growth in revenues and net cash accruals over the past few years. The company's
business model is based on providing integrated solutions to its clients; from
advising on the right packaging material for a particular drug to importing,
processing and printing the material for the client, rather than just supplying
the ordered material.